Sanofi SA (SAN) Receives €79.32 Consensus Price Target from Brokerages

Sanofi SA (EPA:SAN) has earned an average recommendation of “Hold” from the nineteen analysts that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is €79.32 ($92.23).

Several brokerages have commented on SAN. Kepler Capital Markets set a €84.00 ($97.67) target price on Sanofi and gave the stock a “buy” rating in a research note on Monday, August 6th. HSBC set a €72.00 ($83.72) target price on Sanofi and gave the stock a “neutral” rating in a research note on Wednesday, August 1st. Societe Generale set a €90.00 ($104.65) target price on Sanofi and gave the stock a “buy” rating in a research note on Wednesday, August 1st. Cfra set a €75.00 ($87.21) target price on Sanofi and gave the stock a “neutral” rating in a research note on Wednesday, August 1st. Finally, Barclays set a €65.00 ($75.58) target price on Sanofi and gave the stock a “sell” rating in a research note on Wednesday, August 1st.

SAN stock opened at €66.17 ($76.94) on Friday. Sanofi has a fifty-two week low of €63.09 ($73.36) and a fifty-two week high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: Investing strategies using the yield curve

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply